Skip to main content
Premium Trial:

Request an Annual Quote

ABI: Expression Array Formal Launch Likely in January

Premium

Applied Biosystems’ said this week that its Expression Array System, a whole-genome microarray, would likely be launched in January.

“The Expression Array System is currently under evaluation with customer test sites and we anticipate making the formal commercial launch announcement in January,” Lori Murray, an ABI spokeswoman, wrote in an email to BioArray News.

When the company announced in July it was launching this whole-genome microarray, it said the product would be launched by the end of the year. The decision for likely launch in January is not necessarily indicative of a delay in readying the product for the market: late December is not the optimum time for a product launch, according to the company.

ABI displayed the product at Chips to Hits in October. [For details on the product and the announcement, see BAN 11-05-03, 07-30-03]

The Expression Array System is to incorporate 60-mer oligonucleotides, as well as a chemiluminescent detection system for hybridization. It will also be packaged with a microarray analyzer, a database of gene and protein information, and reagents, the company has said.

— MMJ

 

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.